Evidence map›Paper›PMID 29107295›Full record

ArticleMolecular metabolism2017

The FGF21 response to fructose predicts metabolic health and persists after bariatric surgery in obese humans.

Kasper W Ter Horst, Pim W Gilijamse, Ahmet Demirkiran, Bart A van Wagensveld, Mariette T Ackermans, Joanne Verheij, Johannes A Romijn, Max Nieuwdorp, Eleftheria Maratos-Flier, Mark A Herman and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Kasper W Ter HorstDepartment of Endocrinology and Metabolism, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
Pim W GilijamseDepartment of Endocrinology and Metabolism, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
Ahmet DemirkiranDepartment of Surgery, Red Cross Hospital, Vondellaan 13, 1942LE Beverwijk, The Netherlands.
Bart A van WagensveldDepartment of Surgery, OLVG, Postbus 9243, 1006AE Amsterdam, The Netherlands.
Mariette T AckermansDepartment of Clinical Chemistry, Laboratory of Endocrinology, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
Joanne VerheijDepartment of Pathology, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
Johannes A RomijnDepartment of Medicine, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
Max NieuwdorpDepartment of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands; Department of Internal Medicine, VU University Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands; Institute for Cardiovascular Research, VU University Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands.
Eleftheria Maratos-FlierDivision of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Center for Life Sciences, Boston, MA 02215, USA.
Mark A HermanDivision of Endocrinology, Metabolism and Nutrition, Duke University School of Medicine, 300 N. Duke Street, Carmichael Building, Durham, NC 27701, USA.
Mireille J SerlieDepartment of Endocrinology and Metabolism, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. Electronic address: m.j.serlie@amc.nl.
Amsterdam UMC Location University of Amsterdam · NLBeth Israel Deaconess Medical Center · USDuke University · US

Funding

The Role of ChREBP in Fructose Induced Metabolic DiseaseR01DK100425 · NIDDK · DUKE UNIVERSITY · PI HERMAN, MARK A · 2014 to 2023
$3.6M
NIDDK NIH HHS R01 DK100425
6 · The paper itself

Abstract

objectiveFructose consumption has been implicated in the development of obesity and insulin resistance. Emerging evidence shows that fibroblast growth factor 21 (FGF21) has beneficial effects on glucose, lipid, and energy metabolism and may also mediate an adaptive response to fructose ingestion. Fructose acutely stimulates circulating FGF21 consistent with a hormonal response. We aimed to evaluate whether fructose-induced FGF21 secretion is linked to metabolic outcomes in obese humans before and after bariatric surgery-induced weight loss.

methodsWe recruited 40 Roux-en-Y gastric bypass patients and assessed the serum FGF21 response to fructose (75-g fructose tolerance test) and basal and insulin-mediated glucose and lipid fluxes during a 2-step hyperinsulinemic-euglycemic clamp with infusion of [6,6-

resultsSerum FGF21 increased 3-fold at 120 min after fructose ingestion and returned to basal levels at 300 min. Neither basal FGF21 nor the fructose-FGF21 response correlated with liver fat content or liver histopathology, but increased levels were associated with elevated endogenous glucose production, increased lipolysis, and peripheral/muscle insulin resistance. At 1-year follow-up, subjects had lost 28 ± 6% of body weight and improved in all metabolic outcomes, but fructose-stimulated FGF21 dynamics did not markedly differ from the pre-surgical state. The association between increased basal and stimulated FGF21 levels with poor metabolic health was no longer present after weight loss.

conclusionsFructose ingestion in obese humans stimulates FGF21 secretion, and this response is related to systemic metabolism. Further studies are needed to establish if FGF21 signaling is (patho)physiologically involved in fructose metabolism and metabolic health.

Indexed as

AdultBariatric SurgeryBlood GlucoseEnergy MetabolismFatty LiverFemaleFibroblast Growth FactorsFructoseFructose IntoleranceGastric BypassGlucoseHumansInsulinInsulin ResistanceLiverMaleBlood Glucosefibroblast growth factor 21Fibroblast Growth FactorsFructoseGlucoseInsulinFGF21FructoseHyperinsulinemic-euglycemic clampInsulin resistanceObesityTranslational study

Identifiers

PMID29107295
PMCPMC5681276
OpenAlexW2751447132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.